Literature DB >> 30553184

Risk factors for mortality and cost implications of complicated intra-abdominal infections in critically ill patients.

Gennaro De Pascale1, Simone Carelli2, Maria Sole Vallecoccia2, Salvatore Lucio Cutuli2, Temistocle Taccheri2, Luca Montini3, Giuseppe Bello2, Teresa Spanu4, Mario Tumbarello5, Americo Cicchetti6, Irene Urbina7, Marco Oradei8, Marco Marchetti9, Massimo Antonelli10.   

Abstract

PURPOSE: To assess risk factors for 28-day mortality and cost implications in intensive care unit (ICU) patients with complicated intra-abdominal infections (cIAIs).
METHODS: Single-center retrospective cohort study of prospectively collected data analysing ICU patients with a microbiologically confirmed complicated intra-abdominal infections.
RESULTS: 137 complicated intra-abdominal infections were included and stratified according to the adequacy of antimicrobial therapy (initial inadequate antimicrobial therapy [IIAT], n = 44; initial adequate antimicrobial therapy [IAAT], n = 93). The empirical use of enterococci/methicillin-resistant Staphylococcus aureus active agents and of carbapenems was associated with a higher rate of therapeutic adequacy (p = 0.016 and p = 0.01, respectively) while empirical double gram-negative and antifungal therapy did not. IAAT showed significantly lower mortality at 28 and 90 days and increased clinical cure and microbiological eradication (p < 0.01). In the logistic and Cox-regression models, IIAT and inadequate source control were the unique predictors of 28-day mortality. No costs differences were related to the adequacy of empirical therapy and source control. The empirical double gram-negative and antifungal therapy (p = 0.03, p = 0.04) as well as the isolation of multidrug-resistant (MDR) bacteria and the microbiological failure after targeted therapy were drivers of increased costs (p = 0.004, p = 0.04).
CONCLUSIONS: IIAT and inadequate source control are confirmed predictors of mortality in ICU patients with complicated intra-abdominal infections. Empirical antimicrobial strategies and MDR may drive hospital costs.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adequate empirical therapy; Hospital costs; Intra-abdominal infections; Source control

Mesh:

Substances:

Year:  2018        PMID: 30553184     DOI: 10.1016/j.jcrc.2018.12.001

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  5 in total

Review 1.  Antimicrobial Lessons From a Large Observational Cohort on Intra-abdominal Infections in Intensive Care Units.

Authors:  Dirk Vogelaers; Stijn Blot; Andries Van den Berge; Philippe Montravers
Journal:  Drugs       Date:  2021-05-26       Impact factor: 9.546

2.  Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections.

Authors:  Gennaro De Pascale; Lucia Lisi; Gabriella Maria Pia Ciotti; Maria Sole Vallecoccia; Salvatore Lucio Cutuli; Laura Cascarano; Camilla Gelormini; Giuseppe Bello; Luca Montini; Simone Carelli; Valentina Di Gravio; Mario Tumbarello; Maurizio Sanguinetti; Pierluigi Navarra; Massimo Antonelli
Journal:  Ann Intensive Care       Date:  2020-07-13       Impact factor: 6.925

3.  Risk factors for therapeutic failure in the management of post-operative peritonitis: a post hoc analysis of the DURAPOP trial.

Authors:  Philippe Montravers; Marina Esposito-Farèse; Sigismond Lasocki; Nathalie Grall; Benoit Veber; Philippine Eloy; Philippe Seguin; Emmanuel Weiss; Herve Dupont
Journal:  J Antimicrob Chemother       Date:  2021-11-12       Impact factor: 5.790

4.  Endoscopic Stent Placement to Treat Gastric Leak Following Laparoscopic Sleeve Gastrectomy: the Bigger, the Better.

Authors:  Franck Billmann; Adrian Billeter; Anja Schaible; Beat Peter Müller-Stich
Journal:  Obes Surg       Date:  2022-01-28       Impact factor: 3.479

5.  Clinical significance of urinary obstruction in critically ill patients with urinary tract infections.

Authors:  Jun Young Hong; Suk-Won Suh; Jungho Shin
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.